Form D · Biotechnology

Dianthus Therapeutics, Inc.

Waltham, MA · CIK 0001783732

Offering snapshot reported Apr 21, 2022 · SEC filing

Reported sold
$100M
Offering amount: $100M
Investors reported
22
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 6, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 21, 2022Initial$100,000,000No comparison22SEC filing
Jun 7, 2021Initial$14,999,996No comparison6SEC filing
Apr 29, 2021Initial$7,722No comparison1SEC filing
Dec 16, 2020Amendment$6,500,000$4,857,500vs Aug 1, 20196SEC filing
Aug 1, 2019Initial$1,642,500No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$3M
Finders' fees
$0
Form D file number
021-442826

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Jefferies LLC2347Jefferies LLC · CRD 2347

Source: Form D, filed Apr 21, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Marino Garcia Director, Executive
Tomas Kiselak Director
Lei Meng Director
Leon Moulder Director
Leon O. Moulder, Jr. Director
Paula Soteropoulos Director
Kenneth Evan Thompson Executive
Jonathan Violin Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
203 Crescent Street, Bldg #4, Ste 205
Waltham, MA, 02453